{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:57Z","timestamp":1791078897095,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jacl.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T18:59:45Z","timestamp":1440788385000},"page":"832-836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-1932","authenticated-orcid":false,"given":"Samata","family":"Basani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.08.004_bib1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.08.004_bib2","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1210\/en.2008-1540","article-title":"Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein","volume":"150","author":"de Vries-van der Weij","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacl.2015.08.004_bib3","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jacl.2015.08.004_bib4","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.2007.12.2614","article-title":"Randomized phase III trial comparing bexarotene (L1069-49)\/cisplatin\/vinorelbine with cisplatin\/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I","volume":"26","author":"Ramlau","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacl.2015.08.004_bib5","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/01.ATV.0000248101.93488.84","article-title":"The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia","volume":"26","author":"Lalloyer","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.08.004_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1172\/JCI1581","article-title":"Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids","volume":"102","author":"Vu-Dac","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.08.004_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1432-1033.1996.0699h.x","article-title":"Modulation of the activity of the human cholesteryl ester transfer protein by carboxylated derivatives. Evidence for 13-cis-retinoic acid as a potent activator of the protein's activity in plasma","volume":"240","author":"Florentin","year":"1996","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jacl.2015.08.004_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1365-2265.2003.01755.x","article-title":"Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short-term hypothyroidism. Lack of relationship to lipoprotein abnormalities","volume":"58","author":"Dedecjus","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jacl.2015.08.004_bib9","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.08.004_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(00)00603-1","article-title":"HDL-cholesterol as a marker of coronary heart disease risk: the Quebec Cardiovascular Study","volume":"153","author":"Despres","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.08.004_bib11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.08.004_bib12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.08.004_bib13","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.08.004_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.08.004_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0021-9150(94)90144-9","article-title":"Homozygous Tangier disease and cardiovascular disease","volume":"107","author":"Serfaty-Lacrosniere","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.08.004_bib16","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1210\/jc.2011-1846","article-title":"LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals","volume":"97","author":"Haase","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2015.08.004_bib17","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary\u00a0syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.08.004_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0021-9150(03)00020-0","article-title":"Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency","volume":"167","author":"Pisciotta","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.08.004_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jacl.2015.08.004_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415003657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415003657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T19:24:30Z","timestamp":1537385070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415003657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1933287415003657"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.08.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}